Developmental Therapeutics

How to Apply

How to Apply

Apply Online, Mail, or Fax
Read more »

Pre-Graduate Research Programs

Pre-Graduate Research Programs

Pre-Graduate Research Programs
Read more »

Faculty

Faculty

Our research faculty
Read more »

The Developmental Therapeutics Program combines expertise in protein structure and modeling, cancer cell signaling, clinical therapeutics as well as clinical trials, to address the realization that modern drug discovery and development requires a multidisciplinary and interactive process. Co-led by Drs. Gregory Adams, Ph.D., Roger Cohen, M.D., and Erica Golemis, Ph.D., the major focus of the MTM Program is to develop and refine new cancer treatments, integrating the efforts of basic and clinical researchers in a highly collegial environment.

1. Biomolecular Structure and Function

Cartoon of the conformational changes involved
in regulating the binding activity of the signaling adaptor
protein NHERF1

Sequence analysis and structural information can be used to analyze key interactions between proteins associated with cancer phenotypes and to provide us with a better understanding of the mechanisms underlying oncogenic signaling. Experimental structure determination and computational structure prediction can also be used to guide the development of agents such as antibodies or small molecules that can disrupt these interactions or alter mitogenic signaling. A major focus of the Developmental Therapeutics Program is to utilize sophisticated methods to understand protein structures and interactions that underlie, and ultimately inhibit, cancer.
Team Members

2. Cancer Signaling

Network of proteins enriched for determinants of resistance to EGFR-targeting agents

Although historically most clinical trials have been focused on evaluation of single-agent therapies, it is now appreciated that due to the redundancy in cell signaling pathways, better clinical results are more likely if two or more key oncogenic signaling proteins are inhibited simultaneously. A major theme of the Developmental Therapeutics Program is the use of integrated bioinformatics and screening approaches, with the ultimate goal of establishing the structure of drug resistance networks and overcoming such resistance through use of rationally designed targeted therapies. A complementary approach involves delineating novel functions for classic resistance factors that can be exploited for therapeutic gain.
Team Members

3. Clinical Therapeutics

A MRI guided high intensity focused ultrasound
system for tumor ablation and vascular permeability
studies to improve drug delivery and for combined radiotherapy treatment.

A major focus of the Developmental Therapeutics program is to develop and evaluate new agents for the detection and treatment of cancer. The program brings together a highly collaborative team of scientists and physicians to identify drug targets corresponding to areas of significant clinical need, determine critical molecular structures, rationally generate agents that target these structures, evaluate their preclinical potential, translate the most promising agents into the clinic and transmit the knowledge gained from these trials back to the laboratory. Our Phase I program serves as a uniquely rich funnel bringing in novel compounds from both academic labs and the private sector. We have a widely respected and highly experienced team that provides significant intellectual input into Phase I clinical trials, ranging from the design of the protocol through the conduct of the study. The Phase I program has identified and refined a variety of novel treatment approaches with a direct impact on the treatment of human cancer and interacts closely with Developmental Therapeutics program scientists to facilitate the performance of correlative studies.
Team Members